11.11.2022 13:08:05

Regeneron, Sanofi: CHMP Recommends Approval Of Dupixent In The EU

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the approval of Dupixent in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. The positive CHMP opinion is supported by data from two Phase 3 trials, PRIME and PRIME2, the companies noted.

The European Commission is anticipated to announce a final decision on the Dupixent application in the coming months.

For More Such Health News, visit rttnews.com.

Analysen zu Regeneron Pharmaceuticals Inc.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Regeneron Pharmaceuticals Inc. 672,00 -1,06% Regeneron Pharmaceuticals Inc.
Sanofi S.A. (spons. ADRs) 45,60 0,44% Sanofi S.A. (spons. ADRs)
Sanofi S.A. 91,01 -0,12% Sanofi S.A.